Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(25)
DRUG(1)
OTHER(1)
Cisplatin
3 trials
phase_2
washington-university-school-of-medicine
MK-3475 (neoadjuvant)
3 trials
phase_1_2phase_2
washington-university-school-of-medicine
Peripheral blood
2 trials
phase_1_2phase_2
washington-university-school-of-medicine
nab-paclitaxel
2 trials
phase_2
washington-university-school-of-medicine
Nivolumab
2 trials
phase_1_2phase_2
washington-university-school-of-medicine
Tumor biopsy
2 trials
phase_1_2phase_2
washington-university-school-of-medicine
Ramucirumab
2 trials
phase_1_2phase_2
washington-university-school-of-medicine
Cetuximab
2 trials
phase_2
washington-university-school-of-medicine

+9 more interventions

17 unique interventions3 categories

Analytics

Trial Phases

Phase 12
Phase 27

Trial Status

Completed2
Terminated1
Other4

Role Distribution

Principal Investigator7
PI Rate100%

Activity Timeline

Clinical Trials (7)

NCT05980000Phase 2Active Not Recruiting
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
HNSCCMetastatic Head and Neck CancerMetastatic Head-and-neck Squamous-cell Carcinoma+3 more
PrincipalinvestigatorStart date: 2023-10-27
NCT04831320Phase 2Active Not Recruiting
Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor
Metastatic Head-and-neck Squamous-cell Carcinoma
PrincipalinvestigatorStart date: 2021-09-28
NCT03650764Phase 1/2Completed
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
PrincipalinvestigatorStart date: 2019-05-29
NCT03655444Phase 1/2Terminated
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Head and Neck Squamous Cell Carcinoma
PrincipalinvestigatorStart date: 2019-05-29
NCT03389477Phase 2Active Not Recruiting
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
PrincipalinvestigatorStart date: 2018-04-27
NCT02296684Phase 2Completed
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
Cancer of Head and NeckCarcinoma, Squamous Cell of Head and NeckHead and Neck Cancer+3 more
PrincipalinvestigatorStart date: 2015-03-25
NCT02270814Phase 2Active Not Recruiting
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Cancer of the Head and NeckHead and Neck CancerHead and Neck Squamous Cell Carcinoma
PrincipalinvestigatorStart date: 2015-02-02

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Douglas Adkins, M.D.

Washington University School of Medicine

Related
11 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsCancer of Head and Neck+1 more

Worked with same sponsors:

Celgene CorporationMerck Sharp & Dohme LLC+2 more
Similarity Score15%

Nina Bhardwaj, MD, PhD

Icahn School of Medicine at Mount Sinai

Related
8 trials

Shared therapeutic areas:

Cancer of Head and NeckSquamous Cell Carcinoma of Head and Neck
Similarity Score8%

yuankai shi, MD

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Related
17 trials

Shared therapeutic areas:

Squamous Cell Carcinoma of Head and NeckCancer of Head and Neck
Similarity Score8%

Lillian Siu, MD

Princess Margaret Cancer Centre

Related
12 trials

Shared therapeutic areas:

Cancer of Head and NeckSquamous Cell Carcinoma of Head and Neck
Similarity Score8%

Nancy Lee, MD

Memorial Sloan Kettering Cancer Center

Related
18 trials

Shared therapeutic areas:

Cancer of Head and NeckSquamous Cell Carcinoma of Head and Neck
Similarity Score8%

Ye Guo, MD

Fudan University

Related
13 trials

Shared therapeutic areas:

Cancer of Head and NeckSquamous Cell Carcinoma of Head and Neck
Similarity Score8%

Ingrid Mayer, MD

Vanderbilt-Ingram Cancer Center

Related
13 trials

Shared therapeutic areas:

Cancer of Head and Neck
Similarity Score4%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Head and Neck Neoplasms
Similarity Score4%

Scot C. Remick, MD

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Related
13 trials

Shared therapeutic areas:

Cancer of Head and Neck
Similarity Score4%

Corey J. Langer, MD

Fox Chase Cancer Center

Related
16 trials

Shared therapeutic areas:

Cancer of Head and Neck
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (7)

Showing 7 of 7 trials

NCT05980000Phase 2PrincipalInvestigator

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

HNSCCMetastatic Head and Neck CancerMetastatic Head-and-neck Squamous-cell Carcinoma+3 more
Active Not Recruiting
NCT04831320Phase 2PrincipalInvestigator

Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor

Metastatic Head-and-neck Squamous-cell Carcinoma
Active Not Recruiting
NCT03650764Phase 1/2PrincipalInvestigator

Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Completed
NCT03655444Phase 1/2PrincipalInvestigator

Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

Head and Neck Squamous Cell Carcinoma
Terminated
NCT03389477Phase 2PrincipalInvestigator

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma
Active Not Recruiting
NCT02296684Phase 2PrincipalInvestigator

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Cancer of Head and NeckCarcinoma, Squamous Cell of Head and NeckHead and Neck Cancer+3 more
Completed
NCT02270814Phase 2PrincipalInvestigator

Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma

Cancer of the Head and NeckHead and Neck CancerHead and Neck Squamous Cell Carcinoma
Active Not Recruiting

All 7 trials loaded